Collectively, these findings demonstrate that SLE is characterized by mTOR pathway hyperactivation and distinct T cell metabolic reprogramming favoring glycolysis and FAS, which disrupts Th17/Treg balance and drives autoimmunity, positioning metabolic intervention as a viable treatment strategy. The gene discussed is MTOR; the disease is systemic lupus erythematosus.